Sean Duffy Sells 14,960 Shares of Omada Health (NASDAQ:OMDA) Stock

Omada Health, Inc. (NASDAQ:OMDA) CEO Sean Duffy sold 14,960 shares of the business’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $17.36, for a total transaction of $259,705.60. Following the sale, the chief executive officer owned 411,861 shares in the company, valued at $7,149,906.96. The trade was a 3.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Omada Health Trading Up 2.4%

Shares of OMDA traded up $0.41 during trading hours on Thursday, reaching $17.66. The company had a trading volume of 788,759 shares, compared to its average volume of 1,205,677. The firm has a 50 day simple moving average of $15.63 and a 200-day simple moving average of $14.79. The company has a market capitalization of $1.05 billion and a price-to-earnings ratio of -65.41. Omada Health, Inc. has a 12-month low of $10.28 and a 12-month high of $26.92.

Omada Health (NASDAQ:OMDA) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.03. The firm had revenue of $78.05 million during the quarter. Omada Health had a negative net margin of 2.22% and a negative return on equity of 1.82%. Sell-side analysts forecast that Omada Health, Inc. will post -0.01 earnings per share for the current year.

Institutional Investors Weigh In On Omada Health

Several hedge funds have recently modified their holdings of the company. Geode Capital Management LLC acquired a new position in shares of Omada Health in the second quarter valued at approximately $637,000. Walleye Capital LLC acquired a new stake in Omada Health during the second quarter worth approximately $458,000. Ilex Capital Partners UK LLP purchased a new stake in Omada Health in the 2nd quarter worth approximately $201,000. Soros Fund Management LLC purchased a new stake in Omada Health in the 2nd quarter worth approximately $640,000. Finally, Raymond James Financial Inc. acquired a new position in Omada Health in the 2nd quarter valued at $32,000.

Analysts Set New Price Targets

OMDA has been the topic of several research analyst reports. Barclays boosted their price target on Omada Health from $18.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. BMO Capital Markets reduced their price objective on Omada Health from $27.00 to $18.00 and set an “outperform” rating for the company in a report on Friday, March 6th. Needham & Company LLC reiterated a “buy” rating and set a $28.00 target price on shares of Omada Health in a research report on Friday, May 8th. Canaccord Genuity Group set a $24.00 target price on Omada Health in a report on Friday, May 8th. Finally, Morgan Stanley dropped their price target on Omada Health from $32.00 to $30.00 and set an “overweight” rating for the company in a research report on Friday, March 6th. Ten research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $22.91.

About Omada Health

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.